Berberis composition for cognitive health
US-2024424045-A1 · Dec 26, 2024 · US
Genome stability enhancer
US10894067B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10894067-B2 |
| Application number | US-201816494009-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 6, 2018 |
| Priority date | Mar 16, 2017 |
| Publication date | Jan 19, 2021 |
| Grant date | Jan 19, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed is a genome stability enhancer comprising, as an active ingredient, at least one member selected from the group consisting of enzyme-treated royal jelly, gnetum or its extract, and gnetin C.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for enhancing genome stability, comprising the step of administering an effective amount of at least one member selected from the group consisting of enzyme-treated royal jelly, gnetum or its extract, and gnetin C to a mammal in need thereof. 2. The method according to claim 1 , wherein an effective amount of enzyme-treated royal jelly is administered. 3. The method according to claim 1 , wherein an effective amount of gnetum or its extract is administered. 4. The method according to claim 1 , wherein an effective amount of gnetin C is administered. 5. The method according to claim 1 , wherein the enzyme-treated royal jelly is a royal jelly treated with peptidase. 6. The method according to claim 1 , wherein at least one member selected from the group consisting of enzyme-treated royal jelly, gnetum or its extract, and gnetin C is administered in the form of a cosmetic. 7. The method according to claim 1 , wherein at least one member selected from the group consisting of enzyme-treated royal jelly, gnetum or its extract, and gnetin C is administered in the form of a food or beverage. 8. The method according to claim 1 , wherein at least one member selected from the group consisting of enzyme-treated royal jelly, gnetum or its extract, and gnetin C is administered in the form of a drug or quasi-drug.
Assignees
Inventors
Classifications
- A23L33/105Primary
Plant extracts, their artificial duplicates or their derivatives · CPC title
using additives (addition of substantially indigestible substances A23L33/21) · CPC title
Antineoplastic agents · CPC title
containing heterocyclic compounds · CPC title
Anti-Parkinson drugs · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10894067B2 cover?
- Disclosed is a genome stability enhancer comprising, as an active ingredient, at least one member selected from the group consisting of enzyme-treated royal jelly, gnetum or its extract, and gnetin C.
- Who is the assignee on this patent?
- Yamada Bee Co Inc, Nat Cancer Ct, Univ Tohoku
- What technology area does this patent fall under?
- Primary CPC classification A23L33/105. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 19 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).